podophyllotoxin has been researched along with atovaquone in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Brun, R; Carballeira, NM; Herman, R; Kappe, SH; Lauinger, IL; Perozzo, R; Sanabria, D; Tarun, A; Tasdemir, D; Zloh, M | 1 |
2 other study(ies) available for podophyllotoxin and atovaquone
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
Topics: Alkynes; Antimalarials; Binding Sites; Cell Line, Tumor; Computer Simulation; Erythrocytes; Fatty Acid Synthase, Type II; Fatty Acids, Unsaturated; Humans; Kinetics; Liver; Malaria, Falciparum; Plasmodium falciparum; Protozoan Proteins | 2010 |